Drug | Identifier no | Trial status | Trial phase | Control arm | Experiment arm | Patient enrolled |
---|---|---|---|---|---|---|
Axitinib | NCT04562441 | Recruiting | II | n.a | Axitinib + avelumab | R/M NPC |
Camerelizumab | NCT04944914 | Recruiting | III | Camrelizumab | Camrelizumab + SBRT | Metastatic NPC |
NCT03707509 | Ongoing | III | Placebos + gemcitabine + cisplatin | Camrelizumab + gemcitabine + cisplatin | R/M NPC chemo-naïve | |
NCT05011227 | Recruiting | II | n.a | Camrelizumab + chemotherapy + endoscopic surgery | Recurrent NPC | |
NCT04586088 | Recruiting | II | n.a | Camrelizumab + apatinib | R/M NPC | |
NCT04453826 | Recruiting | III | IC (gemcitabine + cisplatin) + CCRT (cisplatin + IMRT) | Camrelizumab + IC (gemcitabine + cisplatin) + CCRT (cisplatin + IMRT) | High risk NPC | |
NCT04782765 | Recruiting | II | n.a | IC (camrelizumab + cisplatin) + CCRT + maintenance therapy (camrelizumab) | NPC with no distant metastasis | |
NCT03427827 | Recruiting | III | Chemoradiotherapy + best supportive care | Chemoradiotherapy + camerelizumab | Locoregionally advanced NPC | |
Capecitabine | NCT02958111 | Ongoing | III | No intervention | capecitabine | Locoregionally advanced NPC |
NCT02973386 | Recruiting | III | CCRT (IMRT + cisplatin) | CCRT (IMRT + cisplatin) + capecitabine | Locally advanced high risk NPC | |
NCT04220528 | Recruiting | II | n.a | IC (gemcitabine) + CCRT (IMRT + nidapatin) + capecitabine/teggio | N3 NPC | |
Cetuximab | NCT02633176 | Recruiting | III | IC (cisplatin + docetaxel) + CCRT (cisplatin) + maintenance therapy (capecitabine) | IC (cetuximab + cisplatin + docetaxel) + CCRT (cetuximab + cisplatin) + maintenance therapy (capecitabine) | Untreated metastatic NPC |
Endostar | NCT02636231 | Ongoing | II | IMRT | Endostar + IMRT | Locally recurrent NPC |
Nimotuzumab | NCT03666221 | Recruiting | II | n.a | Nimotuzumab + IMRT | Recurrent NPC |
NCT04456322 | Recruiting | III | IC (paclitaxel) + CCRT (cisplatin + IMRT) | IC (paclitaxel) + CCRT (nimotuzumab + RT) | Locoregionally advanced low risk NPC | |
NCT04223024 | Ongoing | II | IC (paclitaxel) + CCRT (cisplatin + IMRT) | IC (paclitaxel) + CCRT (cisplatin + IMRT + nimotuzumab) | Advanced high risk NPC | |
NCT03915132 | Recruiting | II | n.a | Nimotuzumab + VMAT (IMRT) | Elderly NPC | |
NCT03708822 | Recruiting | II | n.a | Docetaxel + cisplatin + nimotuzumab | R/M NPC | |
 | NCT03837808 | Recruiting | III | CCRT (IMRT + cisplatin) | IMRT + concurrent nimotuzumab | Stage II and III NPC |
Nivolumab | NCT03097939 | Recruiting | II | n.a | Nivolumab + ipilimumab | EBV-driven NPC |
NCT03267498 | Recruiting | II | n.a | Nivolumab + CCRT (cisplatin) | Stage II–IVB NPC | |
Pembrolizumab | NCT03734809 | Ongoing | II | n.a | IC (pembrolizumab + gemcitabine + cisplatin) + CCRT (cisplatin + pembrolizumab) + maintenance therapy (pembrolizumab) | Untreated stage IVA NPC |
NCT02538510 | Ongoing | I, II | n.a | Pembrolizumab + vorinostat | R/M NPC | |
NCT03849469 | Ongoing | I | XmAb22841 | XmAb22841 + pembrolizumab | Advanced NPC | |
NCT03674567 | Recruiting | I, II | FLX475 | FLX475 + pembrolizumab | Advanced NPC | |
Proton therapy | NCT04870840 | Recruiting | I | n.a | Image-guided hyper-fractioned proton therapy | Locally Advanced NPC |
Toripalimab | NCT04398056 | Ongoing | II | n.a | Chemoradiotherapy (fluorouracil + cisplatin + IMRT) + toripalimab | De novo metastatic NPC |
NCT04376866 | Recruiting | III | CCRT (cisplatin + IMRT) | CCRT (toripalimab + cisplatin + IMRT) + toripalimab | Locoregionally recurrent NPC | |
NCT04517214 | Recruiting | II | Gemcitabine + cisplatin + IMRT + maintenance therapy (capecitabine) | Toripalimab + gemcitabine + cisplatin + IMRT + maintenance therapy (capecitabine + toripalimab) | Metastatic NPC | |
NCT04992988 | Recruiting | II | n.a | Toripalimab + CCRT (cisplatin) | Locoregionally recurrent NPC | |
NCT04778956 | Recruiting | III | Salvage surgery | Salvage surgery + toripalimab | Resectable locally recurrent NPC | |
NCT03925090 | Recruiting | II | CCRT (cisplatin) | CCRT (cisplatin + IMRT + toripalimab) + toripalimab | Locoregionally advanced high risk NPC | |
NCT04405622 | Ongoing | II | n.a | Toripalimab + gemcitabine + maintenance therapy (toripalimab) | R/M NPC | |
NCT04453813 | Recruiting | III | CCRT (cisplatin + IMRT) | CCRT (toripalimab + cisplatin + IMRT) + toripalimab | Unresectable locally recurrent NPC | |
NCT03854838 | Ongoing | II | n.a | IMRT + toripalimab | Unresectable locally recurrent NPC | |
NCT02915432 | Ongoing | I, II | n.a | First line chemotherapy + toripalimab | Advanced NPC | |
NCT03907826 | Recruiting | III | Chemoradiotherapy (gemcitabine + cisplatin + IMRT) | Toripalimab + chemoradiotherapy (gemcitabine + cisplatin + IMRT) | Recurrent NPC | |
Toripalimab | NCT03930498 | Recruiting | II | n.a | Toripalimab + chemoradiotherapy (gemcitabine + cisplatin + IMRT) | Recurrent high risk NPC |
NCT03474640 | Ongoing | I | n.a | Toripalimab | Advanced NPC |